CompanyGraph
Beijing Tong Ren Tang Chinese Medicine Company Ltd.
3613 · HKEX · Hong Kong
Price data from its TQR listing on FSX, quoted in EUR
cm.tongrentang.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleLevered free cash flow is $65.26M, above the global median of $18.73M
- FinancialsHigh structural barrier to entry
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
7.18%Above 5Y avg (3.32%)
Annual Rate
HKD 0.40Paid annual
Payout Ratio
86.1%High
Payback Period
1.5 yr
Last Ex-Dividend
Jun 12, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
7.44BHKD948.61M · vs all stocks (USD)
Trailing P/E
12.99xRevenue (TTM)
1.35BHKD172.53M · vs all stocks (USD)
Profit Margin
26.64%Beta
0.3410xvs all stocks
52-Week Change
-37.63%vs all stocks
Market Capitalization
7.44BHKD948.61M · vs all stocks (USD)
Enterprise Value
2.82BHKD358.99M · vs all stocks (USD)
Trailing P/E
12.99xForward P/E
9.47xPEG Ratio
-0.1299xPrice to Sales (TTM)
3.45xPrice to Book (MRQ)
1.15xEnterprise to Revenue
2.08xEnterprise to EBITDA
6.35xProfit Margin
26.64%Operating Margin
35.82%Return on Assets (TTM)
5.89%Return on Equity (TTM)
8.80%Revenue (TTM)
1.35BHKD172.53M · vs all stocks (USD)
Revenue per Share (TTM)
1.62HKDUpdated Sep 21, 2026Quarterly Revenue Growth
-21.00%Gross Profit (TTM)
847.21MHKD107.99M · vs all stocks (USD)
EBITDA (TTM)
674.26MHKD85.95M · vs all stocks (USD)
Net Income (TTM)
360.55MHKD45.96M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-15.60%Operating Cash Flow (TTM)
621.93MHKD79.28M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
512.00MHKD65.26M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.4000HKDUpdated Sep 21, 2026Trailing Annual Dividend Yield
7.18%vs all stocks
5-Year Average Dividend Yield
3.32%vs all stocks
Payout Ratio
86.05%Minority Interest (Equity)
180.97MHKDFY2025 · Dec 31, 2025EPS (Basic)
0.4700HKDFY2025 · Dec 31, 2025EPS (Diluted)
0.4700HKDFY2025 · Dec 31, 2025Basic Shares Outstanding
837.10MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
837.10MSharesFY2025 · Dec 31, 2025Operating Cash Flow
772.22MHKDFY2025 · Dec 31, 2025Free Cash Flow
731.11MHKDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
2.23BHKDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
504.69MHKDFY2025 · Dec 31, 2025Other Non-cash Items
-41.17MHKDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
58.98MHKDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
249.72MHKDFY2025 · Dec 31, 2025Capital Expenditures
-41.10MHKDFY2025 · Dec 31, 2025Net Investing Cash Flow
-41.10MHKDFY2025 · Dec 31, 2025Long-term Debt Payments
-71.00KHKDFY2025 · Dec 31, 2025Common Dividends Paid
-292.99MHKDFY2025 · Dec 31, 2025Other Financing Charges
8.07MHKDFY2025 · Dec 31, 2025Net Financing Cash Flow
-284.99MHKDFY2025 · Dec 31, 2025Shares Outstanding
837.10MSharesUpdated Sep 21, 2026Float Shares
237.10MSharesUpdated Sep 21, 2026% Held by Insiders
71.68%vs all stocks
% Held by Institutions
3.01%vs all stocks
Total Cash (MRQ)
2.22BHKD282.65M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.65HKDUpdated Sep 21, 2026Total Debt (MRQ)
125.80MHKD16.04M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0297xCurrent Ratio (MRQ)
21.03xBook Value per Share (MRQ)
4.84HKDUpdated Sep 21, 2026Total Assets
4.66BHKD594.10M · vs all stocks (USD)
Total Current Assets
4.06BHKDFY2025 · Dec 31, 2025Total Liabilities
291.88MHKDFY2025 · Dec 31, 2025Total Non-current Assets
595.98MHKDFY2025 · Dec 31, 2025Total Non-current Liabilities
85.03MHKDFY2025 · Dec 31, 2025Total Current Liabilities
206.85MHKDFY2025 · Dec 31, 2025Cash
438.05MHKDFY2025 · Dec 31, 2025Cash Equivalents
1.79BHKDFY2025 · Dec 31, 2025Cash & Cash Equivalents
2.23BHKDFY2025 · Dec 31, 2025Other Short-term Investments
51.38MHKDFY2025 · Dec 31, 2025Accounts Receivable
394.87MHKDFY2025 · Dec 31, 2025Inventory
1.34BHKDFY2025 · Dec 31, 2025Accounts Payable
62.03MHKDFY2025 · Dec 31, 2025Short-term Debt
52.30MHKDFY2025 · Dec 31, 2025Long-term Debt
74.24MHKDFY2025 · Dec 31, 2025Common Stock (Book)
938.79MHKDFY2025 · Dec 31, 2025Retained Earnings
3.30BHKDFY2025 · Dec 31, 2025Total Shareholders' Equity
4.37BHKD556.90M · vs all stocks (USD)
52-Week Low
5.54HKDUpdated Sep 21, 202652-Week High
9.50HKDUpdated Sep 21, 202652-Week Change
-37.63%vs all stocks
Beta
0.3410xvs all stocks
50-Day MA
6.44HKDUpdated Sep 21, 2026200-Day MA
7.55HKDUpdated Sep 21, 2026Avg 10-Day Volume
1.43MSharesUpdated Sep 21, 2026Avg 30-Day Volume
1.19MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
0.4300HKDUpdated Sep 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 0.56
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Levered free cash flow is $65.26M, above the global median of $18.73MNotable
Levered free cash flow (USD): 65,264,623.684Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Suven Life Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Pharma Resources Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cullinan Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Bioventus Inc.
Tier 1ProductionApproval-Gated PipelineRule
Green Cross Corporation
Tier 1ProductionApproval-Gated PipelineRule
KPC Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Kura Oncology Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Arbutus Biopharma Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hangzhou Biotest Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Medincell SA
Tier 1ProductionApproval-Gated PipelineRule